Copyright Notice
Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Bookshelf ID: NBK611172PMID: 39836800
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 552292-08-7
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the use of rolapitant during breastfeeding. Because rolapitant and its metabolites are more than 99% bound to plasma proteins, the amount in milk is likely to be low; however, the binding of its major active metabolite is not known. If the mother requires rolapitant, it is not a reason to discontinue breastfeeding. However, consideration should be given to any chemotherapy the mother is receiving.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Rolapitant
CAS Registry Number
552292-08-7
Drug Class
Breast Feeding
Lactation
Milk, Human
Antiemetics
Neurokinin-1 Receptor Antagonists
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.